LabConnect Builds New Biorepository Facility
The facility features space for ambient, refrigerated, cold and ultra-low temperature storage as well as liquid nitrogen vapor phase storage with storage capacity for more than 8 million samples.
LabConnect, a global central laboratory provider, has built a new biorepository facility to expand services and better meet the evolving needs of the industry. The Johnson City, Tenn.-based facility features space for ambient, refrigerated, cold (-20C) and ultra-low temperature (-70C to -80C) storage as well as liquid nitrogen vapor phase storage (-190C), with storage capacity for more than 8 million samples.
Read the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
